The results of large-scale clinical studies have shown that SGLT2 inhibitors improve hyperglycemia independently of insulin [3,4] and present renoprotective and cardioprotective effects in diabetic patients [5,6,7]. This evidence concerns the gene SLC5A2 and Hyperglycemia.